medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2023-105medsovet-7499Research ArticleГИНЕКОЛОГИЯGYNECOLOGYОпыт применения препарата с пролонгированным высвобождением железа у пациентов с дефицитом железаExperience with the prolonged release of iron in iron deficiency patientshttps://orcid.org/0000-0002-0535-2916ДроздовВ. Н.DrozdovV. N.

Дроздов Владимир Николаевич, д.м.н., профессор, профессор кафедры клинической фармакологии и пропедевтики внутренних болезней 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Vladimir N. Drozdov, Dr. Sci. (Med.), Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

vndrozdov@yandex.ruhttps://orcid.org/0000-0001-6589-7654ШихЕ. В.ShikhE. V.

Ших Евгения Валерьевна, д.м.н., профессор, заведующая кафедрой клинической фармакологии и пропедевтики внутренних болезней 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Evgenia V. Shikh, Dr. Sci. (Med.), Chair of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

chih@mail.ruhttps://orcid.org/0000-0002-7430-3341АстаповскийА. А.AstapovskiiA. A.

Астаповский Александр Алексеевич, к.м.н., ассистент кафедры клинической фармакологии и пропедевтики внутренних болезней 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Alexandr A. Astapovskii, Cand. Sci. (Med.), Assistant of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

al.astapovskii@gmail.comhttps://orcid.org/0000-0002-9460-7289ЦветковД. Н.TsvetkovD. N.

Цветков Дмитрий Николаевич, ассистент кафедры клинической фармакологии и пропедевтики внутренних болезней 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Dmitry N. Tsvetkov, Assistant of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

cvetkovdima282@mail.ruПервый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation20230505202306135143Copyright © Дроздов В.Н., Ших Е.В., Астаповский А.А., Цветков Д.Н., 20232023Дроздов В.Н., Ших Е.В., Астаповский А.А., Цветков Д.Н.Drozdov V.N., Shikh E.V., Astapovskii A.A., Tsvetkov D.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/7499

Дефицит железа является одним из ведущих факторов глобального бремени болезней, затрагивающих преимущественно детей, женщин в пременопаузе и людей с низким и средним уровнем дохода. При длительном железодефиците развивается железодефицитная анемия (ЖДА), которая, по оценкам Всемирной организации здравоохранения (ВОЗ), остается самым распространенным типом анемии во всем мире. К наиболее частым причинам ЖДА относятся желудочно-кишечные кровотечения, менструальная кровопотеря и беременность у женщин. В настоящее время золотым стандартом терапии ЖДА считаются препараты двухвалентного железа. На сегодняшний день существуют препараты двухвалентного железа с замедленным высвобождением. Преимущество данной формы состоит в том, что такие препараты лучше переносятся, у них ниже частота развития побочных эффектов при сопоставимой биодоступности и эффективности по сравнению с обычными формами. К таким препаратам относится Тардиферон®. В проведенном нами исследовании было отмечено, что на фоне приема препарата Тардиферон® уровень ферритина к  концу 1-го месяца терапии у  больных с  ЖДА вырос с  9,7  ±  1,3  до  25,4  ±  5,1  мкг/л, а  к  концу 3-го месяца до 246,7 мкг/л (р ≤ 0,05). Похожую динамику мы отметили в уровне гемоглобина: у больных с ЖДА он вырос с 97,4 ± 9,3 до 125,8 ± 10,2 г/л (р ≤ 0,05) и у 21 (75%) из 28 больных достиг нормальных значений (более 120 г/л) уже к концу 1-го месяца терапии. К 3-му месяцу терапии уже все пациенты с ЖДА достигли целевого уровня, а среднее значение гемоглобина в группе составило 142,1 ± 5,6 г/л (р ≤ 0,05). Таким образом, у пациентов с ЖДА на фоне терапии препаратом Тардиферон® нормализуются показатели гемограммы, увеличивается концентрация гемоглобина и ферритина уже к концу 1-го месяца терапии.

Iron deficiency is one of the leading factors in the global burden of disease, affecting mainly children, premenopausal women and low- and middle-income people. With prolonged iron deficiency, iron deficiency anemia (IDA) develops, which, according to the World Health Organization (WHO), remains the most common type of anemia worldwide. The most common causes of IDA include gastrointestinal bleeding, menstrual blood loss and pregnancy in women. Currently, divalent iron preparations are considered the “gold standard” of IDA therapy. To date, there are preparations of divalent iron with delayed release. The advantage of this form is that such drugs are better tolerated, they have a lower incidence of side effects with comparable bioavailability and efficacy compared to conventional forms. Such drugs include Tardyferon®.In our study, it was noted that against the  background of  taking Tardyferon®, the level of ferritin by the end of the 1st month of therapy in patients with latent iron deficiency increased from 12.4 ± 0.93 to 27.8  ± 4.1 µg/L (p ≤ 0.05). In patients with IDA, it increased from 9.7 ± 1.3 to 25.4 = 5.1 µg/L. By the end of the 3rd month of treatment, the ferritin level in patients with latent iron deficiency was 200.1 ± 30.8 (p < 0.05), and in patients with IDA – 246.7 µg/L (p < 0.05). We noted a similar dynamic in the hemoglobin level: in patients with IDA, it increased from 97.4 ± 9.3 g/L to 125.8 ± 10.2 g/l (p < 0.05), and in 21 (75%) of 28 patients it reached normal values (more than 120 g/L) by the end of the 1st months of therapy.By the 3rd month of  therapy, all patients with IDA had already reached the  target level, and the  average hemoglobin value in  the group was 142.1 ± 5.6 g/L (p = 0.05).Thus, in patients with IDA, against the background of therapy with Tardyferon®, hemogram indicators normalize, the concentration of hemoglobin and ferritin increases by the end of the 1st month of therapy.

дефицит железажелезодефицитная анемияТардиферондвухвалентное железопролонгированное высвобождениеlatent iron deficiencyiron deficiency anemiaTardyferonferrous ironprolonged releaseReferencesMcLean E., Cogswell M., Egli I., Wojdyla D., de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr. 2009;12(4):444–454. https://doi.org/10.1017/S1368980008002401.McLean E., Cogswell M., Egli I., Wojdyla D., de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr. 2009;12(4):444–454. https://doi.org/10.1017/S1368980008002401.Vos T., Abajobir A.A., Abate K.H., Abbafati C., Abbas K.M., Abd-Allah F. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2.Vos T., Abajobir A.A., Abate K.H., Abbafati C., Abbas K.M., Abd-Allah F. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2.Crielaard B.J., Lammers T., Rivella S. Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017;16(6):400–423. https://doi.org/10.1038/nrd.2016.248.Crielaard B.J., Lammers T., Rivella S. Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017;16(6):400–423. https://doi.org/10.1038/nrd.2016.248.Gisbert J.P., Bermejo F., Pajares R., Pérez-Calle J.L., Rodríguez M., Algaba A. et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis. 2009;15(10):1485–1491. https://doi.org/10.1002/ibd.20925.Gisbert J.P., Bermejo F., Pajares R., Pérez-Calle J.L., Rodríguez M., Algaba A. et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis. 2009;15(10):1485–1491. https://doi.org/10.1002/ibd.20925.McLean E., Cogswell M., Egli I., Wojdyla D., de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr. 2009;12(4):444–454. https://doi.org/10.1017/S1368980008002401.McLean E., Cogswell M., Egli I., Wojdyla D., de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr. 2009;12(4):444–454. https://doi.org/10.1017/S1368980008002401.Ershler W.B., Chen K., Reyes E.B., Dubois R. Economic burden of patients with anemia in selected diseases. Value Health. 2005;8(6):629–638. https://doi.org/10.1111/j.1524-4733.2005.00058.x.Ershler W.B., Chen K., Reyes E.B., Dubois R. Economic burden of patients with anemia in selected diseases. Value Health. 2005;8(6):629–638. https://doi.org/10.1111/j.1524-4733.2005.00058.x.Horton S., Ross J. The economics of iron deficiency. Food Policy. 2003;28(1):51–75. https://doi.org/10.1016/S0306-9192(02)00070-2.Horton S., Ross J. The economics of iron deficiency. Food Policy. 2003;28(1):51–75. https://doi.org/10.1016/S0306-9192(02)00070-2.Курилович Е.О., Волкова О.И., Федорова Т.А., Голубцов В.В., Попович Л.Д., Андреева М.Д. и др. Социально-экономические выгоды адекватной коррекции дефицита железа у беременных. Акушерство и гинекология. 2021;(9):212–220. https://doi.org/10.18565/aig.2021.9.212-220.Kurilovich E.O., Volkova O.I., Fedorova T.A., Golubtsov V.V., Popovich L.D., Andreeva M.D. et al. Socioeconomic benefits from adequate correction of iron deficiency in pregnant women. Akusherstvo i Ginekologiya (Russian Federation). 2021;(9):212–220. (In Russ.) https://doi.org/10.1016/s0140-6736(20)32594-0.Pasricha S.-R., Tye-Din J., Muckenthaler M.U., Swinkels D.W. Iron deficiency. Lancet. 2021;397(10270):233–248. https://doi.org/10.1016/s0140-6736(20)32594-0.Pasricha S.-R., Tye-Din J., Muckenthaler M.U., Swinkels D.W. Iron deficiency. Lancet. 2021;397(10270):233–248. https://doi.org/10.1016/s0140-6736(20)32594-0.Grote Beverborg N., van der Wal H.H., Klip I.T., Anker S.D., Cleland J., Dickstein K. et al. Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies. JAMA Cardiol. 2019;4(7):696–701. https://doi.org/10.1001/jamacardio.2019.1739.Grote Beverborg N., van der Wal H.H., Klip I.T., Anker S.D., Cleland J., Dickstein K. et al. Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies. JAMA Cardiol. 2019;4(7):696–701. https://doi.org/10.1001/jamacardio.2019.1739.Cappellini M.D., Musallam K.M., Taher A.T. Iron deficiency anaemia revisited. J Intern Med. 2020;287(2):153–170. https://doi.org/10.1111/joim.13004.Cappellini M.D., Musallam K.M., Taher A.T. Iron deficiency anaemia revisited. J Intern Med. 2020;287(2):153–170. https://doi.org/10.1111/joim.13004.Kiss J.E., Birch R.J., Steele W.R., Wright D.J., Cable R.G. Quantification of body iron and iron absorption in the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion. 2017;57(7):1656–1664. https://doi.org/10.1111/trf.14133.Kiss J.E., Birch R.J., Steele W.R., Wright D.J., Cable R.G. Quantification of body iron and iron absorption in the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion. 2017;57(7):1656–1664. https://doi.org/10.1111/trf.14133.Muckenthaler M.U., Rivella S., Hentze M.W., Galy B. A Red Carpet for Iron Metabolism. Cell. 2017;168(3):344–361. https://doi.org/10.1016/j.cell.2016.12.034.Muckenthaler M.U., Rivella S., Hentze M.W., Galy B. A Red Carpet for Iron Metabolism. Cell. 2017;168(3):344–361. https://doi.org/10.1016/j.cell.2016.12.034.Вартанян А.А. Метаболизм железа, ферроптоз, рак. Российский биотерапевтический журнал. 2017;16(3):14–20. https://doi.org/10.17650/1726-9784-2017-16-3-14-20.Vartanian A.A. Iron metabolism, ferroptosis and cancer. Russian Journal of Biotherapy. 2017;16(3):14–20. (In Russ.) https://doi.org/10.17650/1726-9784-2017-16-3-14-20.Aschemeyer S., Qiao B., Stefanova D., Valore E.V., Sek A.C., Ruwe T.A. et al. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood. 2018;131(8):899–910. https://doi.org/10.1182/blood-2017-05-786590.Aschemeyer S., Qiao B., Stefanova D., Valore E.V., Sek A.C., Ruwe T.A. et al. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood. 2018;131(8):899–910. https://doi.org/10.1182/blood-2017-05-786590.Guida C., Altamura S., Klein F.A., Galy B., Boutros M., Ulmer A.J. et al. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood. 2015;125(14):2265–2275. https://doi.org/10.1182/blood-2014-08-595256.Guida C., Altamura S., Klein F.A., Galy B., Boutros M., Ulmer A.J. et al. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood. 2015;125(14):2265–2275. https://doi.org/10.1182/blood-2014-08-595256.Harvey L.J., Armah C.N., Dainty J.R., Foxall R.J., John Lewis D., Langford N.J., Fairweather-Tait S.J. Impact of menstrual blood loss and diet on iron deficiency among women in the UK. Br J Nutr. 2005;94(4):557–564. https://doi.org/10.1079/bjn20051493.Harvey L.J., Armah C.N., Dainty J.R., Foxall R.J., John Lewis D., Langford N.J., Fairweather-Tait S.J. Impact of menstrual blood loss and diet on iron deficiency among women in the UK. Br J Nutr. 2005;94(4):557–564. https://doi.org/10.1079/bjn20051493.O’Brien B., Mason J., Kimble R. Bleeding Disorders in Adolescents with Heavy Menstrual Bleeding: The Queensland Statewide Paediatric and Adolescent Gynaecology Service. J Pediatr Adolesc Gynecol. 2019;32(2):122–127. https://doi.org/10.1016/j.jpag.2018.11.005.O’Brien B., Mason J., Kimble R. Bleeding Disorders in Adolescents with Heavy Menstrual Bleeding: The Queensland Statewide Paediatric and Adolescent Gynaecology Service. J Pediatr Adolesc Gynecol. 2019;32(2):122–127. https://doi.org/10.1016/j.jpag.2018.11.005.Goddard A.F., James M.W., McIntyre A.S., Scott B.B. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10): 1309–1316. https://doi.org/10.1136/gut.2010.228874.Goddard A.F., James M.W., McIntyre A.S., Scott B.B. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10): 1309–1316. https://doi.org/10.1136/gut.2010.228874.Kiss J.E., Vassallo R.R. How do we manage iron deficiency after blood donation? Br J Haematol. 2018;181(5):590–603. https://doi.org/10.1111/bjh.15136.Kiss J.E., Vassallo R.R. How do we manage iron deficiency after blood donation? Br J Haematol. 2018;181(5):590–603. https://doi.org/10.1111/bjh.15136.Ahmad Fuzi S.F., Koller D., Bruggraber S., Pereira D.I., Dainty J.R., Mushtaq S. A 1-h time interval between a meal containing iron and consumption of tea attenuates the inhibitory effects on iron absorption: a controlled trial in a cohort of healthy UK women using a stable iron isotope. Am J Clin Nutr. 2017;106(6):1413–1421. https://doi.org/10.3945/ajcn.117.161364.Ahmad Fuzi S.F., Koller D., Bruggraber S., Pereira D.I., Dainty J.R., Mushtaq S. A 1-h time interval between a meal containing iron and consumption of tea attenuates the inhibitory effects on iron absorption: a controlled trial in a cohort of healthy UK women using a stable iron isotope. Am J Clin Nutr. 2017;106(6):1413–1421. https://doi.org/10.3945/ajcn.117.161364.Haider L.M., Schwingshackl L., Hoffmann G., Ekmekcioglu C. The effect of vegetarian diets on iron status in adults: A systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2018;58(8):1359–1374. https://doi.org/10.1080/10408398.2016.1259210.Haider L.M., Schwingshackl L., Hoffmann G., Ekmekcioglu C. The effect of vegetarian diets on iron status in adults: A systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2018;58(8):1359–1374. https://doi.org/10.1080/10408398.2016.1259210.Lam J.R., Schneider J..L, Quesenberry C.P., Corley D.A. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency. Gastroenterology. 2017;152(4):821–829.e1. https://doi.org/10.1053/j.gastro.2016.11.023.Lam J.R., Schneider J..L, Quesenberry C.P., Corley D.A. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency. Gastroenterology. 2017;152(4):821–829.e1. https://doi.org/10.1053/j.gastro.2016.11.023.Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832–1843. https://doi.org/10.1056/NEJMra1401038.Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832–1843. https://doi.org/10.1056/NEJMra1401038.Elstrott B., Khan L., Olson S., Raghunathan V., DeLoughery T., Shatzel J.J. The role of iron repletion in adult iron deficiency anemia and other diseases. Eur J Haematol. 2020;104(3):153–161. https://doi.org/10.1111/ejh.13345.Elstrott B., Khan L., Olson S., Raghunathan V., DeLoughery T., Shatzel J.J. The role of iron repletion in adult iron deficiency anemia and other diseases. Eur J Haematol. 2020;104(3):153–161. https://doi.org/10.1111/ejh.13345.Лукина Е.А., Цветаева Н.В., Двирнык В.Н., Румянцев А.Г., Масчан А.А., Чернов В.М. и др. Железодефицитная анемия – 2021–2022–2023: клинические рекомендации. 2021. Режим доступа: http://gbpokachi.ru/upload/medialibrary/81b/hmct9ew0cod31zwgy2y2skydhvgcn4gk.pdf.Lukina E.A., Tsvetaeva N.V., Dvirnyk V.N., Rumyantsev A.G., Maschan A.A., Chernov V.M. et al. Iron deficiency anaemia: clinical guidelines 2021/2022/2023. 2021. (In Russ.) Available at: http://gbpokachi.ru/upload/medialibrary/81b/hmct9ew0cod31zwgy2y2skydhvgcn4gk.pdf.Peyrin-Biroulet L., Williet N., Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585–1594. https://doi.org/10.3945/ajcn.114.103366.Peyrin-Biroulet L., Williet N., Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585–1594. https://doi.org/10.3945/ajcn.114.103366.Резолюция совета экспертов по железодефицитной анемии у женщин. Акушерство и гинекология: новости, мнения, обучение. 2020;8(4):28–36. https://doi.org/10.24411/2303-9698-2020-14004.Expert council resolution on iron-deficiency anemia in women Obstetrics and Gynecology: News, Opinions, Training. 2020;8(4):28–36. (In Russ.) https://doi.org/10.24411/2303-9698-2020-14004.Jaeggi T., Kortman G.A., Moretti D., Chassard C., Holding P., Dostal A. et al Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64(5):731–742. https://doi.org/10.1136/gutjnl-2014-307720.Jaeggi T., Kortman G.A., Moretti D., Chassard C., Holding P., Dostal A. et al Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64(5):731–742. https://doi.org/10.1136/gutjnl-2014-307720.Лебедев В.В., Демихов В.Г., Дмитриев А.В., Аиари М., Фомина М.А. Сравнительная эффективность и безопасность применения препаратов двух- и трехвалентного железа для лечения железодефицитной анемии (обзор литературы). Вопросы гематологии/онкологии и иммунологии в педиатрии. 2016;15(4):5–12. Режим доступа: https://www.phdynasty.ru/en/catalog/magazines/pediatrichematology-oncology-and-immunopathology/2016/volume-15-issue-4/29682.Lebedev V.V., Demikhov V.G., Dmitriev A.V., Aiari M., Fomina M.A. A comparative efficacy and safety of using ferrous and ferric iron preparations for management of iron-deficiency anaemia. Pediatric Haematology/Oncology and Immunopathology. 2016;15(4):5–12. (In Russ.) Available at: https://www.phdynasty.ru/en/catalog/magazines/pediatric-hematologyoncology-and-immunopathology/2016/volume-15-issue-4/29682.Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. Scientific World Journal. 2012;2012:846824. https://doi.org/10.1100/2012/846824.Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. Scientific World Journal. 2012;2012:846824. https://doi.org/10.1100/2012/846824.Cappellini M.D., Santini V., Braxs C., Shander A. Iron metabolism and iron deficiency anemia in women. Fertil Steril. 2022;118(4):607–614. https://doi.org/10.1016/j.fertnstert.2022.08.014.Cappellini M.D., Santini V., Braxs C., Shander A. Iron metabolism and iron deficiency anemia in women. Fertil Steril. 2022;118(4):607–614. https://doi.org/10.1016/j.fertnstert.2022.08.014.Auerbach M., Adamson J.W. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31–38. https://doi.org/10.1002/ajh.24201.Auerbach M., Adamson J.W. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31–38. https://doi.org/10.1002/ajh.24201.Дворецкий Л.И., Заспа Е.А. Алгоритмы диагностики и лечения железодефицитных анемий. Фарматека. 2006;(5):117–120. Режим доступа: https://pharmateca.ru/ru/archive/article/6487?ysclid=lg26p6z9vz358434247.Dvoreckii L.I., Zaspa E.A. Algorithms for diagnostic testing and treatment of iron-deficiency anaemia. Farmateka. 2006;(5):117–120. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/6487?ysclid=lg26p6z9vz358434247.Fayed H.M., Aly S.S., Ahmed S.S., Abdella A.H., Tamam A.-A.E., Mohmmed N.A. Effects of oral iron (ferrous versus ferric) supplementation on oxidative stress and antioxidant status in pregnant women with iron deficiency: controlled trial. Egypt J Haematol. 2016;41(2):31–41. Available at: https://www.researchgate.net/publication/305346661_Effects_of_oral_iron_ferrous_versus_ferric_supplementation_on_oxidative_stress_and_antioxidant_status_in_pregnant_women_with_iron_deficiency_controlled_trial.Fayed H.M., Aly S.S., Ahmed S.S., Abdella A.H., Tamam A.-A.E., Mohmmed N.A. Effects of oral iron (ferrous versus ferric) supplementation on oxidative stress and antioxidant status in pregnant women with iron deficiency: controlled trial. Egypt J Haematol. 2016;41(2):31–41. Available at: https://www.researchgate.net/publication/305346661_Effects_of_oral_iron_ferrous_versus_ferric_supplementation_on_oxidative_stress_and_antioxidant_status_in_pregnant_women_with_iron_deficiency_controlled_trial.Cancelo-Hidalgo M.J., Castelo-Branco C., Palacios S., Haya-Palazuelos J., Ciria-Recasens M., Manasanch J., Pérez-Edo L. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013;29(4):291–303. https://doi.org/10.1185/03007995.2012.761599.Cancelo-Hidalgo M.J., Castelo-Branco C., Palacios S., Haya-Palazuelos J., Ciria-Recasens M., Manasanch J., Pérez-Edo L. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013;29(4):291–303. https://doi.org/10.1185/03007995.2012.761599.Patra C.N., Priya R., Swain S., Jena G.K., Panigrahi K.C., Ghose D. Pharmaceutical significance of eudragit: A Review. Fut J Pharm Sci. 2017;3(1):33–45. https://doi.org/10.1016/j.fjps.2017.02.001.Patra C.N., Priya R., Swain S., Jena G.K., Panigrahi K.C., Ghose D. Pharmaceutical significance of eudragit: A Review. Fut J Pharm Sci. 2017;3(1):33–45. https://doi.org/10.1016/j.fjps.2017.02.001.Krafft A., Perewusnyk G., Hänseler E., Quack K., Huch R., Breymann C. Effect of postpartum iron supplementation on red cell and iron parameters in non-anaemic iron-deficient women: a randomised placebo-controlled study. BJOG. 2005;112(4):445–450. https://doi.org/10.1111/j.1471-0528.2005.00301.x.Krafft A., Perewusnyk G., Hänseler E., Quack K., Huch R., Breymann C. Effect of postpartum iron supplementation on red cell and iron parameters in non-anaemic iron-deficient women: a randomised placebo-controlled study. BJOG. 2005;112(4):445–450. https://doi.org/10.1111/j.1471-0528.2005.00301.x.Тютюнник В.Л., Кан Н.Е., Михайлова О.И. Коррекция железодефицитной анемии у беременных. Акушерство и гинекология. 2018;(8):106–110. https://doi.org/10.18565/aig.2018.8.106-110.Tyutyunik V.L., Kan N.E., Mikhailova O.I. Correction of iron-deficiency anemia in pregnant women. Akusherstvo i Ginekologiya (Russian Federation). 2018;(8):106–110. (In Russ.) https://doi.org/10.18565/aig.2018.8.106-110.Leary A., Barthe L., Clavel T., Sanchez C., Issiakhem Z., Paillard B., Edmond JM. Iron Pharmacokinetics in Women with Iron Deficiency Anaemia Following A Single Oral Dose of a Novel Formulation of Tardyferon (Prolonged Release Ferrous Sulphate). Drug Res (Stuttg). 2017;67(11):647–652. https://doi.org/10.1055/s-0043-113636.Leary A., Barthe L., Clavel T., Sanchez C., Issiakhem Z., Paillard B., Edmond JM. Iron Pharmacokinetics in Women with Iron Deficiency Anaemia Following A Single Oral Dose of a Novel Formulation of Tardyferon (Prolonged Release Ferrous Sulphate). Drug Res (Stuttg). 2017;67(11):647–652. https://doi.org/10.1055/s-0043-113636.

The authors declare that there are no conflicts of interest present.